{"id":"NCT02706873","sponsor":"AbbVie","briefTitle":"A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate","officialTitle":"A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Na誰ve Subjects With Moderately to Severely Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-23","primaryCompletion":"2018-03-15","completion":"2022-11-10","firstPosted":"2016-03-11","resultsPosted":"2019-10-04","lastUpdate":"2023-07-07"},"enrollment":1002,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Placebo to Upadacitinib","otherNames":[]},{"type":"DRUG","name":"Methotrexate","otherNames":[]},{"type":"DRUG","name":"Placebo to Methotrexate","otherNames":[]},{"type":"DRUG","name":"Upadacitinib","otherNames":["ABT-494","Rinvoq"]}],"arms":[{"label":"Methotrexate","type":"ACTIVE_COMPARATOR"},{"label":"Upadacitinib 7.5 mg (Japan-only)","type":"EXPERIMENTAL"},{"label":"Upadacitinib 15 mg","type":"EXPERIMENTAL"},{"label":"Upadacitinib 30 mg","type":"EXPERIMENTAL"}],"summary":"The objectives of Period 1 were the following:\n\n* To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of RA in methotrexate-na誰ve adults with moderately to severely active RA;\n* To compare the efficacy of upadacitinib 15 mg QD monotherapy and upadacitinib 30 mg QD monotherapy versus weekly methotrexate monotherapy for prevention of structural progression in methotrexate-na誰ve adults with moderately to severely active RA.\n\nThe objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 7.5 mg QD (for participants in Japan only), 15 mg QD, and 30 mg QD in adults with RA who have completed Period 1.","primaryOutcome":{"measure":"Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12 - Global Analysis","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Methotrexate","deltaMin":28.3,"sd":null},{"arm":"Upadacitinib 15 mg","deltaMin":52.1,"sd":null},{"arm":"Upadacitinib 30 mg","deltaMin":56.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":290,"countries":["United States","Argentina","Australia","Belarus","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Czechia","Estonia","Germany","Greece","Guatemala","Hong Kong","Hungary","Ireland","Israel","Italy","Japan","Kazakhstan","Latvia","Lithuania","Mexico","New Zealand","Poland","Portugal","Puerto Rico","Romania","Russia","Serbia","Slovakia","Slovenia","South Africa","Spain","Switzerland","Taiwan","Tunisia","Turkey (T端rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["32638504","40875187","39075620","37982966","37945286","37308218","36754548","36715850","36125701","34897366","34041702","33313898","33115760","31610021"],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":314},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","URINARY TRACT INFECTION","BLOOD CREATINE PHOSPHOKINASE INCREASED","HYPERTENSION"]}}